OVERVIEW

Advancements in hematopathology based on molecular and genetic information are rapidly evolving, making it challenging to keep up with the latest developments and their implications for diagnosis and therapy. This meeting will focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, revisions, and new categories in the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition, Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi, will discuss notable updates, modifications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice.

TARGET AUDIENCE

Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology, and other specialties

LEARNING OBJECTIVES

• At the end of this activity, participants should be able to:

  • Recognize the indicators/markers and molecular tests to look for in complex cases to aid in diagnosis
  • When appropriate, incorporate recent molecular, immunophenotypic, and genetic information when interpreting results, determining diagnoses, and selecting therapies
  • Discuss the latest advances related to the characteristics of hematopoietic malignancies

ACCREDITATION

Temple Health is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

For more information please visit the official event page.